Evidence Table 131. KQ3—Dichotomous—Flatulence

| **Author Year****Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug****(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Roth200960Parallel | NR | Unclear | Fenofibrates (130) | Omega-3 | 84 | 1 | Placebo | 83 | 3 |  |  | Medium |
| Di Spirito200819Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 |  | No Treatment | 50 |  | NR | No treatment related trends regarding ECG or other clinical or laboratory markers were found (no specific data) | Medium |
| Tankanow200365Crossover | N/A | At low risk for CHD (0-1 risk factors) | Digoxin (0.25) | Hawthorn | 8 | 1 | No Treatment | 8 | 0 |  |  | Medium |
| Mueller199151Crossover | N/A | Mixed:Low and/or Moderate | ASA (325 – single dose) | Omega-3 |  | 0 | Placebo |  | 1 |  |  | Medium |